ERBB2 and breast carcinoma: A significant proportion of patients (41%) presenting to the Cambridge Breast Unit with HER2-positive early-stage breast cancer received neo-adjuvant endocrine therapy or chemotherapy on MDT recommendation, and were therefore excluded from the present study.